meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
Apilimod
corticosteroids
ciclesonide
dexamethasone
Dexamethasone 12mg
dexamethasone 6mg
Hydrocortisone
low-dose corticosteroids
methylprednisolone
Immunostimulants drugs
Immunosuppressants drugs
inhaled corticosteroids
Kinase inhibitors
leflunomide
meplazumab
pirfenidone
Polyinosinic-Polycytidylic Acid
sargramostim
statins
thymosin
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
potential COVID-19 treatments
anti-inflammatoty and immuno-therapy
corticosteroids
dexamethasone
dexamethasone 6mg
Immunosuppressants drugs
anti-interleukin-6
tocilizumab
control
placebo
standard of care
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
age >= 60 yr
autoimmune disease
invasive ventilation
no oxygen needed
non invasive oxygen
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Yildiz, 2021
randomized controlled trial
no clinically relevant endpoint
Yildiz E
Indian J Otolaryngol Head Neck Surg 2021 Jul 10;1-6.
10.1007/s12070-021-02749-9